No Serious Adverse Events Related to Treatment with Nitric Oxide Reported Compelling Preliminary Data on Key Secondary Endpoint of 6-Minute Walk NEW YORK, Nov. 27, 2017, AITB, (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that preliminary results from its NO-NTM Phase 2 study in Nontuberculous Mycobacteria (NTM) targeting patients suffering from Mycobacterium Abscessus Complex (MABSC)Read more
- American Premium Water Corporation (OTC Pink: HIPH) Announces International Distribution Agreement
- Pura Naturals Showcases Pura Marine Products at the 72nd Annual Fred Hall Show in Long Beach, CA
- Marijuana Company of America Announces the Offical Launch of Benihemp at the ASD Trade Show
- American Cannabis Company, Inc. Secures New Online Distribution Channels with Walmart, The Home Depot and Amazon for SoHum Living Soils and Dr. Marijane Root Probiotic
- Adama Technologies Announces Successful Up-List to OTCQB
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More